Media Center

Several innovative drugs and new indications from Hansoh Pharma were included in the 2022 National Reimbursable Drug List

Hansoh Pharma's CD19 mAb Xinyue opens a new era of reimbursable drugs for rare disease NMOSD

Hansoh Pharma: EQRx's marketing authorization application for aumolertinib for the treatment of NSCLC with epidermal growth factor mutations was accepted by the EMA

Innovative drugs contribute to one half of its revenue; in-house R&D and external BD collaboration both enter the fast lane - what's behind this pharmaceutical company's success?

Place less emphasis on generic drugs and centralized procurement and more emphasis on R&D - Hansoh Pharma is accelerating its transformation

Hansoh Pharma's Hengmu entered the list of "The 14th Healthy China Forum · Top 10 New Drugs"

Ambrisentan Localized: China Approves First-to-market Ambrisentan Generic (Punuoan) of Hansoh Pharma

Innovative Oncology Drug Breaks Foreign Monopoly